Redwood Pharma Investor Relations Material

Redwood Pharma AB focuses on developing innovative ophthalmic therapies, particularly for dry eye disease (DED). Utilizing its patented IntelliGel technology, the company aims to enhance drug delivery, allowing for reduced dosages and decreased dosing frequency, thus minimizing potential systemic toxicities. Redwood Pharma's strategy involves early-stage clinical development with the intent to license its products to larger pharmaceutical firms for global distribution. Redwood Pharma is headquartered in Stockholm, Sweden, and its shares are listed on the Nasdaq Stockholm.